Background. Children with Epstein-Barr virus (EBV) viremia after hematopoietic stem cell transplantation (HSCT) are at increased risk of post-transplant lymphoproliferative disease (PTLD). Our aim was to assess whether pre-emptive rituximab reduced EBV-viral load (EBV-VL) and the risk of developing PTLD.
Methods. We retrospectively included all children who had a positive EBV-VL within 12 months after an allogenic HSCT (2007 HSCT ( -2015 in a single tertiary pediatric hospital. Whole blood EBV-VL was monitored weekly using a real-time PCR, during the first 100 days after HSCT and then monthly until 6 months post-HSCT or until EBV-VL became undetectable. EBV-VL clearance was defined as two negative EBV-VL at least 1 week apart. Pre-emptive rituximab was defined as a treatment administered before the occurrence of PTLD. We determined the impact of pre-emptive rituximab on EBV-VL clearance, using a marginal structural cox model, adjusting for age at transplant, time between transplant and first positive EBV-VL, in-vivo T-cell depletion at induction, value of EBV-VL at the first dose of rituximab, and the EBV-VL value at the current and previous time point.
Results. Of 214 children who underwent allogenic HSCT, EBV DNA was detected in 87 (41%) children. Children who received rituximab after diagnosis of PTLD were excluded, leading to a cohort of 78 children. Twenty-two (28%) children received pre-emptive rituximab. Mean (SD) age was similar in both groups (10 [5] year). First post-transplant positive EBV-VL was earlier in the pre-emptive rituximab group (mean of 55 [54] vs. 113 [96] days; P < 0.05) and first positive EBV-VL was higher in the pre-emptive rituximab group (mean of 3.4 [0.6] vs. 3.0 [0.6] log 10 /mL; P < 0.05). In adjusted analyses, pre-emptive rituximab was associated with a higher likelihood of EBV-VL clearance (hazard ratio 1.86; 95% confidence interval 1.10-3.14; Figure 1 ). Of the 10 children who developed PTLD, none had received pre-emptive rituximab.
Conclusion. EBV viremia is frequent in children with allogenic HSCT. Our results suggest that pre-emptive rituximab is associated with more rapid EBV-VL clearance. The effect of rituximab on the risk of PTLD needs to be better defined. Figure 1 . Inverse probability of EBV viremia clearance in children. Background. Clostridium difficile infection (CDI) is a major cause of infectious diarrhea especially among allogenic stem cell transplant (SCT) recipients. The relationship between CDI and acute Graft vs. Host Disease (aGvHD) has been a topic of great interest for some time, as either of the two conditions may affect the other. We studied the temporal relation of CDI on aGvHD in the first 100 days posttransplant in a large cohort of allogeneic SCT recipients.
Methods. We conducted an analysis of retrospective data extracted from the medical records of adult patients (more than 18 years of age) who underwent their first allogenic SCT between January 1, 2010 and December 30, 2016 at the University of Kansas Health System. Patients were followed for CDI events between day −10 to day +100 of allogenic transplant. Diagnosis and staging of aGvHD were determined based on standardized aGvHD grading scale utilizing clinical and pathological information between day 0 and day +100. Analysis included descriptive statistics, multivariable logistic regression, and survival analysis with CDI as a time-dependent variable.
Results.: A total of 656 allogenic SCT recipients were included in the analysis. Of the total sample, 419 (64%) developed aGvHD within the first 100 days. CDI was observed in 112 (17%) of all allogenic SCT recipients, 72 (64%) of CDI cases developed prior to the onset of aGvHD. Fidaxomicin was used in the treatment of 57 (50%), whereas, vancomycin was used in 53 (47%) of CDI cases. On unadjusted analysis, CDI was associated with aGvHD (P = 0.0036), high grade aGvHD (P = 0.0132), and GI aGvHD (P = 0.0003). On multivariate survival analysis, the following predictors were associated with aGvHD: CDI (adjusted Hazard Ratio (aHR) = 1.44, P = 0.0047), matched unrelated donor vs. matched related donor transplant type (aHR = 1.40, P = 0.0023), myeloablative vs. reduced intensity conditioning (aHR = 1.87, P < 0.0001). This was consistent with the stepwise logistic regression model.
Conclusion. Allogenic SCT recipients with CDI have a higher risk of aGvHD compared with those without CDI.
Disclosures. All authors: No reported disclosures. Background. TNFα inhibitors are a well-known risk factor for active tuberculosis but less is known about the link between TNFα inhibitors and other mycobacterial diseases, particularly M. marinum. With the increase in use of these medications, and the trend toward more outdoors activities that include aquatic environment exposure, focus should be on better understanding of the link between use of TNFα inhibitors and the development of a severe M. marinum infection that might require earlier diagnosis and more aggressive antibiotic therapy.
Our Experience With M. marinum Cutaneous Infections in Three Patients
Methods. We will describe our experience with three cases of aggressive cutaneous M. marinum infection in patients taking anti-TNFα that presented to Abington Memorial Hospital in Pennsylvania between 2014 and 2017.
Results. Age, gender, diagnosis Background. Antimicrobial stewardship programs are nonexistent in most resource limited settings like Ethiopia. This has resulted in inappropriate use of antibiotics and widespread development of antibiotic resistance. Targeted initiatives surrounding antimicrobial use are needed to tackle this global health threat. Therefore, a program was established to generate data on antibiotic consumption, resistance, and facilitate appropriate use of antibiotics at an academic hospital in northwestern Ethiopia.
Methods. A committee was developed with a multidisciplinary team of clinicians, microbiologist, pharmacists and nurses. A baseline assessment of antibiotic use in the hospital was conducted through review of patient prescriptions and antibiotic inventory changes over time. To understand patterns, listed indication for use was recorded. Clinical audits, provider feedback mechanisms, and a quarterly antibiogram were also developed.
Results. Among 384 records of patients with infectious diseases, 250 adult and 134 pediatric cases were identified. Community acquired pneumonia (CAP) was the most common reason for use of antibiotics, accounting for 33.6% of adults and 22.2% of pediatric cases. Cephalosporins and penicillins were used in adults with CAP in 48.8% and 51.2% of cases, respectively, with or without macrolides or tetracycline. For severe CAP (30 cases), WHO or IDSA guideline concordance was identified as follows: appropriate antibiotic selection in 23 (76.6%), appropriate treatment duration in 15 (50.0%), and timely switch to oral therapy in 20 (66.7%) of the cases. The quarterly antibiogram included 516 bacterial isolates over one year. The most common organisms were Staphylococcus aureus and Escherichia coli, accounting for 34.7% and 16.8% isolates, respectively. The challenges faced in establishing the program were lack of electronic medical records for tracking antibiotic use and inconsistent supply of microbiologic reagents for microbial surveillance.
Conclusion. An effective antimicrobial stewardship program can be established in a resource limited setting with a committed team. Data generated by the program will be used to guide appropriate use of antibiotics and design interventions.
Disclosures. All authors: No reported disclosures. Background. ASPs optimize antibiotic use, achieve best outcomes, minimize adverse effects, reduce costs, and limit pressures contributing to the emergence AMR. SHEA, IDSA, and PIDS recommend mandatory implementation of ASP throughout healthcare institutions. The objective was to describe antimicrobial stewardship-related lessons learnt in light of interventions made during the first year of implementation of an ASP at the Princess Margaret Hospital in Nassau, Bahamas.
Implementation of an Antimicrobial Stewardship Program (ASP) at the Princess Margaret Hospital, Nassau Bahamas
Methods. Prospective audit of antimicrobial use with feedback and intervention was the strategy employed by antimicrobial stewardship between November 2016 and September 2017. The clinical pharmacist monitored patients on adult medical, surgical wards, and critical care unit for the use of carbapenems, vancomycin, antipseudomonal cephalosporins, piperacillin-tazobactam, fluoroquinolones, intravenous fluconazole, amphotericin B, and acyclovir. Antimicrobial stewardship rounds were done by the ID physicians and clinical pharmacist in order to make recommendations to the clinical team. These included de-escalation, escalation of antimicrobial therapy, infectious diseases consultation recommendations, and pharmacokinetic dosing. Acceptability of prospective and feedback recommendations, time to intervention, and patients socio-demographics were also obtained.
Results. Eighty-eight patients were seen during this period in which 52 (59.1%) were females and 36 (40.9%) males. One hundered two recommendations were made by the antimicrobial stewardship team. Of these, 53 (52%) patient interventions were made. Forty-nine (48%) patients were reviewed and left on therapy. Antimicrobial stewardship interventions included de-escalation 22 (41.5%), ID consultation 21 (39.6%), escalation 7 (13.2%), and pharmacokinetic dosing 3 (5.7%). 16 (73%) de-escalation of therapy was accepted and 6 (27%) not accepted. The mean number of days that antimicrobials were administered before intervention was 3 (range: 0-18 days).
Conclusion. An ASP is a feasible strategy to reduce emerging antimicrobial resistance in The Bahamas. Implementing an ASP in The Bahamas is practical and may result in significant de-escalation of antimicrobial therapy. The way forward is to formalize ASP into a sustainable, structured program within the institution.
Disclosures. Background. Surveillance and characterization of bacterial isolates are the preliminary approaches to optimize the use of antibiotics and guide both clinical and institutional decisions surrounding the perspicacious use of antibiotics. We sought to describe the local prevalence of bacterial resistance to direct our stewardship interventions.
Methods. ResearchApproval was obtained from Ministry of Health, Sultanate of Oman. We surveyed all bacterial isolates collected by microbiology laboratory of Sohar Hospital (450-bed tertiary care facility serving patients of northern Oman) between January 1, 2016 to December 31, 2017. Acquired data included; patient demographics, requesting ward, relevant dates (admission, discharge, sample request and collection, result release), specimen type, isolate identification, and sensitivity. Samples from the same patient collected within less than a week with identical phenotype were excluded.
Results. Isolates (n = 15,733) were Gram-positive 29%, Gram-negative 67%, Candida species 23%, other fungi 0.3%, mycobacteria 0.4%. Of Gram-positive group, Staphylococcus aureus (MSSA 27% and MRSA16%), S. agalactiae 25%, coagulase negative staphylococci 12% and others (18 organisms) 19%. Vancomycin was active against 99% of tested isolates. Of Gram-negative group, E. coli 32%, P. aeruginosa 22%, K. pneumoniae 19%, A. baumannii 5%, P. mirabilis 4%, and others (57 organisms) 13%. Extended spectrum β-lactamase production was detected in 12% of cases, while phenotypic colorimetric testing revealed 4% carbapenemase production. Critical care units accommodated 70% of cases with carbapenem resistance infections consisting of 43% pneumonia, 27% blood stream infections, and 12% urinary tract infections.
Conclusion. Vancomycin resistance is limited, cefazolin, and other β-lactams are appropriate empirical agents for a wide range of cases, adequate vancomycin dosing and monitoring should be emphasized to hinder resistance development. Increasing number of carbapenem-resistant cases are being encountered, necessitating consideration of early detection and treatment, appropriate alternative agents and combinations, in addition to a multi-disciplinary approach to treat these recalcitrant infections.
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